Muhammad Ali Ibrahim Kazi | Medicine and Dentistry | Research Excellence Award

Dr. Muhammad Ali Ibrahim Kazi | Medicine and Dentistry | Research Excellence Award

Anne Arundel Medical Center | United States

Dr. Muhammad Ali Ibrahim Kazi, MD, MBBS is a PGY-2 Internal Medicine resident at Anne Arundel Medical Center, Maryland, with strong academic training from Aga Khan University and international clinical experience. He has successfully completed all USMLE steps and is actively engaged in outcomes-based and real-world evidence research, particularly in gastroenterology, hepatology, inflammatory bowel disease, metabolic disorders, and GLP-1–based therapies. Dr. Kazi has multiple peer-reviewed publications, including PubMed-indexed articles and book chapters, and an extensive portfolio of ongoing multicenter cohort studies using large databases such as TriNetX. His work has been presented at major global forums including DDW, ACG, and AASLD. Beyond academia, he demonstrates strong societal impact through leadership in health education, cancer awareness, homelessness outreach, and global community service initiatives.

ORCID Profile

Featured Publications

Peijie He | Medicine and Dentistry | Innovation Excellence Award

Prof. Dr. Peijie He | Medicine and Dentistry | Innovation Excellence Award

ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China

Professor Peijie He, MD, PhD, is a senior surgeon, clinician-scientist, and academic leader in laryngology and head & neck surgery at the Eye and ENT Hospital of Fudan University, Shanghai. As Chief Physician of the Division of Laryngology, his career integrates advanced clinical practice, translational research, and postgraduate medical education, with a sustained focus on function-preserving treatment strategies for laryngeal and hypopharyngeal diseases. His academic training spans China and South Korea, combining clinical otolaryngology with laser medicine and photodynamic therapy, which has shaped his distinctive interdisciplinary research profile. Professor He has made substantial contributions to minimally invasive laryngeal surgery, phonosurgery, and laser-based therapies, particularly the clinical application of CO₂ and KTP lasers, photodynamic therapy, and office-based interventions for vocal fold leukoplakia, papillomatosis, hemangioma, and early-stage laryngeal carcinoma. His work bridges clinical innovation with mechanistic research, elucidating oxidative stress, ROS-mediated pathways, and apoptosis mechanisms in laryngeal cancer cells, thereby strengthening the scientific foundation of modern laryngological treatments. He has authored and co-authored over 30 peer-reviewed international publications in leading journals such as The Laryngoscope, Journal of Voice, European Archives of Oto-Rhino-Laryngology, Lasers in Medical Science, and Oncology Letters, with multiple papers as corresponding author. His research is frequently cited and widely recognized within the otolaryngology community. Professor He has served as Principal Investigator on multiple competitive grants, including projects funded by the National Natural Science Foundation of China and the Shanghai Municipal Health Commission, supporting both basic and clinically translational research.

Citation Metrics (Scopus)
600
500
300

100

Citations
602
Documents
52
h-index
14

Citations

Documents

h-index

View Scopus Profile

Featured Publications

Ahmed A Holiel | Dentistry | Research Excellence Award

Assist. Prof. Dr. Ahmed A Holiel | Dentistry | Research Excellence Award

Alexandria University, Beirut Arab University | Egypt

Assist. Prof. Dr. Ahmed A. Holiel is an accomplished academic and clinician specializing in Restorative and Esthetic Dentistry, with a core research focus on biomaterials, pulp regeneration, digital dentistry, and adhesive restorative systems. He earned his Bachelor’s degree with honors from the Faculty of Dentistry, Alexandria University, followed by a Master’s and Ph.D. in Restorative & Esthetic Dentistry from the same institution. Notably, he became the first researcher at Alexandria University’s Faculty of Dentistry to be exempted from Ph.D. thesis defense after publishing two articles in top-tier ISI journals. Dr. Holiel has progressed through a solid academic career pathway, beginning as a Demonstrator and later assuming roles as Assistant Lecturer and Lecturer at Alexandria University. He currently serves as an Assistant Professor of Restorative & Esthetic Dentistry at Beirut Arab University, Lebanon. He has also contributed internationally as a visiting lecturer at multiple institutions, including the Arab Academy for Science, Technology & Maritime Transport. His contributions to research are significant, with numerous peer-reviewed publications in well-recognized journals covering tissue engineering, biomimetic materials, laser dentistry, pulp regeneration, and emerging technologies in dental science. His work includes multiple clinical trials, in vitro studies, systematic reviews, meta-analyses, and innovation-driven translational research. He also serves as a peer reviewer for leading scholarly journals and acts as Guest and Lead Editor for notable international journals, demonstrating his expertise and academic leadership. Dr. Holiel’s teaching portfolio includes undergraduate, postgraduate, and international credit-hour programs, with roles as course director and coordinator in various operative and esthetic dentistry modules. His clinical experience extends to digital workflows, CAD/CAM systems, smile design, and laser-assisted restorative procedures. A recipient of several distinctions, including the Egyptian Hatton Award and multiple institutional recognitions, Dr. Holiel is an active member of global professional bodies such as the International Association for Dental Research (IADR) and the Tissue Engineering and Regenerative Medicine Society.

Profiles: Scopus | ORCID | Google Scholar

Featured Publications

Grawish, M. E., Grawish, L. M., Grawish, H. M., Grawish, M. M., Holiel, A. A., Sultan, N., … (2022). Demineralized dentin matrix for dental and alveolar bone tissues regeneration: An innovative scope review. Tissue Engineering and Regenerative Medicine, 19(4), 687–701.

Holiel, A. A., Mahmoud, E. M., Abdel-Fattah, W. M., & Kawana, K. Y. (2021). Histological evaluation of the regenerative potential of a novel treated dentin matrix hydrogel in direct pulp capping. Clinical Oral Investigations, 25(4), 2101–2112.

Holiel, A. A., Mahmoud, E. M., & Abdel-Fattah, W. M. (2021). Tomographic evaluation of direct pulp capping using a novel injectable treated dentin matrix hydrogel: A 2-year randomized controlled clinical trial. Clinical Oral Investigations, 25(7), 4621–4634.

Morsy, N., & Holiel, A. A. (2023). Color difference for shade determination with visual and instrumental methods: A systematic review and meta-analysis. Systematic Reviews, 12(1), 95.

Abbassy, K. M., Elmahy, W. A., & Holiel, A. A. (2023). Evaluation of the proximal contact tightness in class II resin composite restorations using different contact forming instruments: A 1-year randomized controlled clinical trial. BMC Oral Health, 23(1), 729.

Shaobing Hua | Medicine and Dentistry | Best Innovation Award

Prof. Dr. Shaobing Hua | Medicine and Dentistry | Best Innovation Award

Hangzhou Dalton Biosciences Ltd | China

Prof. Dr. Shaobing Hua is a distinguished biomedical scientist and innovator whose career spans more than three decades of impactful contributions to molecular biology, therapeutic antibody discovery, and advanced diagnostic technologies. Trained as a molecular biologist with postdoctoral experience at leading U.S. research institutions, he has played a pivotal role in translating fundamental discoveries into clinically deployable solutions. His early work advanced the understanding of signal transduction, proteasome regulation, and gene expression in protozoan parasites, laying the foundation for subsequent research in therapeutic antibody platforms, which led to multiple U.S. and international patents for novel humanized antibodies and high-throughput screening methods. Prof. Hua is widely recognized for developing next-generation hybrid capture technologies and innovative HPV testing platforms that have transformed cervical cancer screening, particularly in resource-limited settings. Under his scientific leadership, DALTON BioSciences has introduced a suite of diagnostic products for cervical cancer, endometrial carcinoma, pre-eclampsia, and vaginitis, contributing to the health of nearly 30 million women. His portfolio includes over 30 peer-reviewed publications in journals such as Journal of Biological Chemistry, Clinical Cancer Research, Protein Science, and Oncogene, and several dozens of patents granted in the United States, China, and the PCT system. His work has been cited widely by researchers across molecular diagnostics, oncology, and immunotechnology. Throughout his career, Prof. Hua has collaborated extensively with major clinical institutions, including leading hospitals affiliated with Zhejiang University, Peking University, the Chinese Academy of Medical Sciences, and several provincial oncology centers. He has served in key roles in national research programs, including China’s 863 Program, national key research plans, and major public health initiatives focused on cervical cancer elimination. His contributions have significantly advanced women’s health diagnostics, strengthened public health infrastructures, and accelerated the global adoption of innovative molecular screening technologies. Prof. Hua’s research, leadership, and translational impact continue to shape the future of precision diagnostics and global health innovation.

Profile: ORCID

Featured Publications

Liu, S., Han, B., Jin, D. Q., Li, L. W., Ge, T. T., Shou, Y. J., Ye, J. M., Zhang, L., & Hua, S. B. (2025). Design and development of a target amplification-free microfluidic platform for multiplex nucleic acids detection: A new generation of hybrid capture immunoassay. Journal of Medical Virology.

Ding, L., Lin, Y. H., Azam, M., Sheridan, J., Wei, S., Gupta, G., Singh, R. K., Pauling, M. H., Chu, A., Tran, A., Yu, N., Hu, J., Wang, W., Long, H., Xiang, D., Zhu, L., & Hua, S. B. (2010). Generation of high-affinity fully human anti-human interleukin-8 antibodies from its cDNA by two-hybrid screening and affinity maturation in yeast. Protein Science, 19, 1957–1966.

Vaday, G. G., Hua, S. B., Peehl, D. M., Pauling, M. H., Lin, Y. H., Zhu, L., Lawrence, D. M., Foda, H. D., & Zucker, S. (2004). CXCR4 and CXCL12 (SDF-1) in prostate cancer: Inhibitory effects of human single-chain Fv antibodies. Clinical Cancer Research, 10, 5630–5639.

Xia, C., Ma, W., Wang, F., Hua, S. B., & Liu, M. (2001). Identification of a prostate-specific G-protein coupled receptor in prostate cancer. Oncogene, 20, 5903–5907.

Xia, C., Bao, Z., Tabassam, F., Ma, W., Qiu, M., Hua, S. B., & Liu, M. (2000). GCIP, a novel human Grap2 and Cyclin D interacting protein, regulates E2F-mediated transcriptional activity. Journal of Biological Chemistry, 275, 20942–20948.

Johanna Gaß | Dentistry | Best Researcher Award

Dr. Johanna Gaß | Dentistry | Best Researcher Award

Private Practice, Germany

Dr. Johanna Alexandra Gaß, M.Sc., is an emerging expert in periodontology, implant therapy, and aesthetic restorative dentistry, recognized for her evidence-based approach and scientific precision. She completed her Doctorate in Medicine (magna cum laude) at the University Hospital Heidelberg, where her research focused on the prognostic relevance of genetic signatures in head and neck squamous cell carcinoma—an interdisciplinary study bridging molecular oncology and clinical outcomes. Her academic foundation is strengthened by a Master of Science in “Parodontologie und Implantattherapie” from the Dresden International University (DIU), awarded with highest distinction. Professionally, Dr. Gaß has gained extensive clinical and research experience through her work in leading dental and periodontal practices in Frankfurt and Berlin, combining clinical excellence with innovative methodologies in advanced implantology and minimally invasive periodontal therapy. Dr. Gaß has contributed several peer-reviewed publications in high-impact journals such as International Journal of Cancer and Clinical Advances in Periodontics, alongside conference presentations at prestigious national meetings including the DGParo Annual Congress. Her research on ceramic veneer restorations in periodontally compromised patients and cathepsin-related mechanisms in periodontal disease demonstrates her ability to integrate translational research with clinical applicability. With growing scholarly recognition, her academic output includes multiple collaborative works with leading clinicians and researchers across Germany, emphasizing the importance of interdisciplinary integration between basic science and clinical dentistry. Her research and clinical practice focus on digitalization in dental workflows, regenerative periodontal therapy, and personalized treatment planning—fields central to the modernization of oral healthcare. As a B. Braun Foundation Scholar and Young Speaker for the ARPA Foundation, she has demonstrated leadership and commitment to advancing professional education. Dr. Gaß’s contributions extend beyond the clinic, influencing dental science through research, teaching, and innovation, aimed at improving global oral health outcomes and promoting sustainable, patient-centered dentistry.

Profile: ORCID

Featured Publications

  1. Bäumer, A. M., Riemer, C. T., Büsch, C., Körner, G. A., & Gaß, J. A. (2025). Patient satisfaction among periodontally stable patients with veneer restorations—A retrospective study. Clinical Advances in Periodontics.

  2. Gaß, J. A., Büsch, C., Körner, G. A., & Bäumer, A. M. (2023). Ceramic anterior veneer restorations in periodontally compromised patients: A retrospective study. Clinical Advances in Periodontics.

  3. Plath, M., Gaß, J., Hlevnjak, M., Li, Q., Feng, B., Pastor Hostench, X., Bieg, M., Schroeder, L., Holzinger, D., Zapatka, M., et al. (2021). Unraveling most abundant mutational signatures in head and neck cancer. International Journal of Cancer, 148(1).

Dr. Johanna Gaß’s work bridges scientific research and clinical innovation in periodontology and implant therapy, advancing evidence-based, minimally invasive treatments that enhance long-term oral health outcomes. Her integration of digital dentistry, regenerative approaches, and translational research fosters global progress toward personalized, sustainable, and patient-centered dental care.

Gabriele Cortina | Medicine and Dentistry | Best Researcher Award

Dr. Gabriele Cortina | Medicine and Dentistry | Best Researcher Award

Humanitas Castelli, Italy

Dr. Gabriele Cortina is an accomplished Orthopaedic and Traumatology Specialist recognized for his excellence in sports medicine, knee surgery, and joint reconstruction. He obtained his secondary diploma with distinction from Istituto Magistrale Luigi Pietrobono in Alatri (2006–2011) and earned his Laurea Magistrale a Ciclo Unico in Medicina e Chirurgia with 110/110 e lode from the Università Campus Bio-Medico di Roma in 2017, followed by professional qualification as a Medico-Chirurgo from Università degli Studi di Roma Tor Vergata (2018) and a specialization in Orthopaedics and Traumatology with 50/50 e lode from Campus Bio-Medico di Roma in 2023. Professionally, he serves as an orthopaedic surgeon at Cliniche Humanitas Gavazzeni-Castelli in Bergamo, Clinica Pierangeli in Pescara, and Clinica Santa Teresa in Isola del Liri, while also completing a prestigious Sport Medicine and Knee Surgery Fellowship at ICATME, Barcelona, under Prof. J.C. Monllau. His previous roles include specialization training at Humanitas Gavazzeni and Castelli Clinics and observerships in shoulder and hip surgery at Clinica Villa Verde (Fermo) and Villa Ulivella (Firenze). Dr. Cortina’s research interests focus on orthopaedic biomechanics, joint preservation, rehabilitation protocols, and regenerative therapies. His notable publications include studies on rotator cuff repair, osteoarthritis, kinematic knee alignment, and adipose tissue injection therapy in reputed journals such as The Knee, Osteology, Journal of Surgical Case Reports, and Journal of Experimental Orthopaedics. He is fluent in Italian and proficient in English and has actively participated in international conferences and cadaveric training courses across Europe, including SIAGASCOT, CADLAB Cologne, and M.O.R.E. Knee Learning Center. His research skills encompass clinical data analysis, surgical innovation, and multidisciplinary collaboration. Honors include multiple cum laude academic distinctions and recognition as a finalist in the LiGca-Lab Program by SIAGASCOT. In conclusion, Dr. Cortina embodies the fusion of clinical precision and academic depth, contributing to the advancement of modern orthopaedics through evidence-based practice, cross-border collaboration, and a lifelong commitment to improving musculoskeletal health.

Profiles: Scopus|ORCID

Featured Publications

  1. Cortina, G., Antuofermo, S. M., Papalia, G. F., Cortina, R., Condello, V., Perelli, S., Monllau, J. C., & Madonna, V. (2025). Limited clinical benefit of medial meniscus posterior root repair combined with high tibial osteotomy in varus knee osteoarthritis: A systematic review and meta‐analysis. Journal of Experimental Orthopaedics.
  2. Cortina, G., Collarile, M., Condello, V., Orlandi, R., Russo, A., Madonna, V., & Pieracci, N. (2021). Spinal hematoma after total knee arthroplasty: A case report. Journal of Surgical Case Reports.
  3. Berton, A., De Salvatore, S., Candela, V., Cortina, G., Lo Presti, D., Massaroni, C., Petrillo, S., & Denaro, V. (2020). Delayed rehabilitation protocol after rotator cuff repair. Osteology, 1(1), 3.
  4. Cortina, G. (2020). Physical activity for the treatment of chronic low back pain in elderly patients: A systematic review. Journal of Clinical Medicine, 9(4), 1023.
  5. Cortina, G. (2019). New trends in treatment of osteoarthritis: “From cells to metal”. A case report of simultaneous different approach to bilateral hip osteoarthritis. Annals of Case Report.

Dr. Gabriele Cortina’s work advances the field of orthopaedic science through innovative approaches in joint reconstruction, sports medicine, and regenerative therapy, bridging clinical excellence with translational research. His contributions enhance surgical outcomes, improve patient mobility, and foster global innovation in minimally invasive and evidence-based orthopaedic care.

Willi Tarver | Medicine and Dentistry | Best Researcher Award

Dr. Willi Tarver | Medicine and Dentistry | Best Researcher Award

Assistant Professor from The Ohio State University, United States

Dr. Willi L. Tarver is a distinguished Assistant Professor in the Division of Cancer Prevention and Control at The Ohio State University, where he leverages his interdisciplinary expertise to address disparities in healthcare delivery and cancer outcomes. With a strong foundation in public health informatics, behavioral oncology, and medical library sciences, Dr. Tarver’s research focuses on integrating patient-reported outcomes (PROs), electronic tools, and equity-focused interventions to better engage underserved populations in the cancer care continuum. His professional trajectory includes advanced fellowships in behavioral oncology and medical informatics, and he is actively involved in federally funded research projects. Dr. Tarver is also deeply committed to mentoring students and early-career professionals, especially from underrepresented backgrounds. His scholarly work addresses systemic issues in healthcare access and aims to develop scalable, tech-based strategies to reduce disparities. In addition to research and teaching, he plays key roles in administrative and clinical improvement initiatives within OSU’s Quality Improvement Hub. Dr. Tarver’s growing leadership within national organizations, innovative approach to equitable cancer prevention, and consistent focus on translating research into real-world applications position him as a leader in academic medicine and public health. He is a compelling nominee for the Best Researcher Award.

Professional Profile

Education

Dr. Tarver’s educational background reflects a unique and valuable combination of public health, information science, and communication, which together form the backbone of his interdisciplinary research. He earned his Doctor of Public Health (Dr.P.H.) from the University of Alabama at Birmingham, where he was also a recipient of the prestigious NCI Diversity Supplement under the Cancer Prevention and Control Training Program. Prior to this, he completed dual Master’s degrees in Public Health (MPH) and Library and Information Science (MLIS) at the University of South Florida. His foundational undergraduate training includes a B.A. in Communication from Columbus State University and an A.S. in Pre-Pharmacy from Gordon College. Dr. Tarver further sharpened his expertise through two postdoctoral fellowships: one in Behavioral Oncology at Indiana University and another in Medical Informatics at the VA Medical Center in Indianapolis. These fellowships provided him with advanced training in clinical research, data analytics, and healthcare system improvement. His broad and deep academic background allows him to bridge clinical research, informatics, and patient-centered interventions—a combination that has enabled his innovative work in cancer disparities and technology-enhanced health solutions.

Professional Experience

Dr. Tarver’s professional journey is defined by a blend of academic, clinical, and administrative roles that support his contributions to cancer prevention, health equity, and public health informatics. Currently serving as an Assistant Professor in the Division of Cancer Prevention and Control within the Department of Internal Medicine at The Ohio State University, he has held this role since 2019. Prior to this appointment, he was a postdoctoral and informatics fellow at the Roudebush VA Medical Center and Indiana University–Purdue University Indianapolis. During his time at the VA, Dr. Tarver contributed to the Center for Health Information and Communication, refining his expertise in applying informatics to support equitable healthcare delivery. His professional roles also extend into quality improvement, where he co-led the Health Equity Core at OSU’s Quality Improvement Hub from 2022 to 2024. Dr. Tarver is an active mentor in OSU’s Center for Cancer Health Equity Summer Research Program, guiding underrepresented students in impactful, community-focused projects. In addition, he participates in institutional governance as a member of OSU’s Innovation Council. Across his roles, he has demonstrated consistent leadership, interdisciplinary collaboration, and a deep commitment to improving health outcomes through equitable and data-driven approaches.

Research Interests

Dr. Tarver’s research is driven by a deep commitment to eliminating disparities in cancer prevention and control through the integration of technology, public health, and clinical practice. His primary interest lies in the development and evaluation of patient-centered technologies—particularly electronic patient-reported outcomes (ePRO) tools—to better engage underserved populations and inform health system decision-making. His projects explore how these tools can be tailored to the unique needs of minority communities, improve cancer survivorship planning, and enhance real-time communication between patients and providers. Another major area of interest is health equity, where Dr. Tarver investigates the impact of perceived discrimination, systemic biases, and cultural barriers on cancer care utilization and outcomes. Additionally, he is involved in research that evaluates educational interventions designed to reduce STEM-related biases in high school learning environments. Through his interdisciplinary work, Dr. Tarver aims to generate actionable insights that not only contribute to academic knowledge but also guide policy reforms and clinical practices. His interests span behavioral oncology, implementation science, and medical informatics, positioning him at the forefront of translational research that impacts patient lives while advancing health equity on a systemic scale.

Research Skills

Dr. Tarver possesses a robust skill set in both qualitative and quantitative research methodologies, which he applies to projects at the intersection of health equity, informatics, and cancer prevention. He is highly experienced in designing and analyzing patient-reported outcomes (PROs), particularly within underserved and minority populations. His expertise includes conducting structured interviews, participant observation, and systematic reviews—skills he actively shares as a guest lecturer in OSU’s Public Health Informatics course. Dr. Tarver is also proficient in research related to intervention development and evaluation, including randomized trials and implementation science frameworks. His grant-writing capabilities are demonstrated by his role as Principal Investigator (PI) and Co-Investigator (Co-I) on several federal and institutional research awards. He collaborates across disciplines, including clinical medicine, education, behavioral science, and information systems, to build comprehensive research designs. Additionally, he has applied informatics tools for data visualization, regulatory decision-making, and game-based learning assessments. These skills empower him to execute complex, multilevel projects with real-world applicability and high translational value. His research toolkit is complemented by strong mentorship abilities, fostering new talent and promoting equity-focused research within academic and clinical settings.

Awards and Honors

Dr. Tarver has received multiple prestigious honors that reflect his academic excellence, research promise, and commitment to advancing health equity. He was honored with the Young Investigator Award at the VA Medical Center in Indianapolis, recognizing his early-career contributions to cancer prevention research. His selection for the VA Advanced Fellowship in Medical Informatics further highlights his potential as a leader in data-driven health solutions. As a fellow in Behavioral Oncology at Indiana University, he gained national recognition for his work integrating psychological, behavioral, and technological approaches to patient-centered care. Notably, he was a recipient of the Diversity Supplement from the National Cancer Institute (NCI) through the University of Alabama at Birmingham, affirming his focus on minority health and health disparities. Earlier in his academic journey, he was awarded the ALSTARS Scholarship at the University of South Florida for academic merit and leadership. These accolades not only reflect his dedication to research excellence but also underscore the national recognition he has received for addressing some of the most pressing challenges in health equity, cancer care, and public health education.

Conclusion

In conclusion, Dr. Willi L. Tarver stands out as an exceptionally well-rounded and impactful academic professional whose contributions significantly advance the fields of cancer prevention, public health informatics, and health equity. His ability to bridge research, mentorship, education, and clinical innovation uniquely qualifies him for the Best Researcher Award. Through interdisciplinary training, funded research projects, and active mentorship, Dr. Tarver continues to address real-world health disparities and improve patient outcomes, particularly in underserved communities. His track record as a Principal Investigator and collaborator on diverse research grants highlights his leadership and collaborative capabilities. Moreover, his mentorship of minority students and involvement in institutional quality improvement initiatives reflect a long-term investment in both people and systems. With a growing portfolio of honors, active society memberships, and educational contributions, Dr. Tarver is positioned for continued excellence and recognition in the academic and public health communities. His work exemplifies the values of translational research, social impact, and scientific integrity, making him a deserving and distinguished candidate for the Best Researcher Award.

Publications Top Notes

1. Family structure and risk behaviors: the role of the family meal in assessing likelihood of adolescent risk behaviors
📅 Year: 2014
✍️ Authors: S. Goldfarb, W.L. Tarver, B. Sen
📰 Psychology Research and Behavior Management, pp. 53–66
📈 Citations: 83

2. The use of cancer-specific patient-centered technologies among underserved populations in the United States: systematic review
📅 Year: 2019
✍️ Authors: W.L. Tarver, D.A. Haggstrom
📰 Journal of Medical Internet Research, 21(4), e10256
📈 Citations: 68

3. Growth dynamics of patient-provider internet communication: trend analysis using the Health Information National Trends Survey (2003 to 2013)
📅 Year: 2018
✍️ Authors: W.L. Tarver, T. Menser, B.W. Hesse, T.J. Johnson, E. Beckjord, E.W. Ford, et al.
📰 Journal of Medical Internet Research, 20(3), e109
📈 Citations: 56

4. A systematic review of the association between family meals and adolescent risk outcomes
📅 Year: 2015
✍️ Authors: S.S. Goldfarb, W.L. Tarver, J.L. Locher, J. Preskitt, B. Sen
📰 Journal of Adolescence, 44, pp. 134–149
📈 Citations: 56

5. Exploring disparities and variability in perceptions and self-reported colorectal cancer screening among three ethnic subgroups of US Blacks
📅 Year: 2010
✍️ Authors: C.K. Gwede, C.M. William, K.B. Thomas, W.L. Tarver, G.P. Quinn, et al.
📰 Oncology Nursing Forum, 37(5), 581
📈 Citations: 51

6. A randomized trial to compare a tailored web-based intervention and tailored phone counseling to usual care for increasing colorectal cancer screening
📅 Year: 2018
✍️ Authors: V.L. Champion, S.M. Christy, W. Rakowski, W.G. Gathirua-Mwangi, W.L. Tarver, et al.
📰 Cancer Epidemiology, Biomarkers & Prevention, 27(12), 1433–1441
📈 Citations: 35

7. The impact of health information technology on cancer care across the continuum: a systematic review and meta-analysis
📅 Year: 2016
✍️ Authors: W.L. Tarver, N. Menachemi
📰 Journal of the American Medical Informatics Association, 23(2), 420–427
📈 Citations: 35

8. Perceptions of colorectal cancer among three ethnic subgroups of US blacks: a qualitative study
📅 Year: 2011
✍️ Authors: C.K. Gwede, E. Jean-Francois, G.P. Quinn, S. Wilson, W.L. Tarver, K.B. Thomas, et al.
📰 Journal of the National Medical Association, 103(8), 669–680
📈 Citations: 35

9. Allostatic load: a framework to understand breast cancer outcomes in Black women
📅 Year: 2021
✍️ Authors: S. Obeng-Gyasi, W. Tarver, R.C. Carlos, B.L. Andersen
📰 NPJ Breast Cancer, 7(1), 100
📈 Citations: 34

10. Factors associated with adherence to mammography screening among insured women differ by income levels
📅 Year: 2018
✍️ Authors: W. Gathirua-Mwangi, A. Cohee, W.L. Tarver, A. Marley, E. Biederman, et al.
📰 Women’s Health Issues, 28(5), 462–469
📈 Citations: 34

Zachariah Chowdhury | Medicine and Dentistry | Best Researcher Award

Dr. Zachariah Chowdhury | Medicine and Dentistry | Best Researcher Award

Professor, Dept Of Oncopathology from Mahamana Pandit Madan Mohan Malviya Cancer Centre (Tata Memorial Hospital) Varanasi, India

Dr. Zachariah Chowdhury is an accomplished academician, clinician, and researcher in the field of oncopathology, currently serving as the Professor and Officer-in-Charge of the Department of OncoPathology at the Mahamana Pandit Madan Mohan Malaviya Cancer Centre (MPMMCC) & Homi Bhabha Cancer Hospital (HBCH) in Varanasi, under the Tata Memorial Centre. With foundational training in MBBS and MD in Pathology from Assam Medical College and a UICC Fellowship in Oncopathology, he has demonstrated an unwavering commitment to excellence in pathology and cancer diagnostics. His extensive teaching background includes instruction at multiple academic levels, including DM, MD, MBBS, nursing, and laboratory technology programs. Dr. Chowdhury has amassed an impressive portfolio of over 50 peer-reviewed publications, addressing both common and rare oncological conditions, contributing significantly to the evolving understanding of oncopathology. He is recognized for his comprehensive approach that merges histopathology, cytopathology, hematopathology, and molecular pathology. As a reviewer, invited speaker, and research presenter at both national and international platforms, he exemplifies the qualities of a dedicated and visionary medical researcher. His contributions to both clinical practice and research make him a pivotal figure in the Indian medical community and a strong candidate for national and international honors in the field of cancer pathology.

Professional Profile

Education

Dr. Chowdhury’s academic journey began with outstanding scholastic achievements, securing the 5th rank in his Higher Secondary School Examination from Cotton College, Guwahati, with a remarkable 83.6% score. He earned his MBBS from Assam Medical College under Dibrugarh University in 2004, ranking 2nd in his final examinations. His dedication to medical sciences continued with an MD in Pathology in 2011 from the same institution, where he again demonstrated academic excellence by clearing all examinations in his first attempt. Complementing his postgraduate training, Dr. Chowdhury was awarded the prestigious UICC/Dr. Praful Desai Fellowship in Oncopathology at Tata Memorial Centre, Mumbai, where he further honed his expertise in histopathology, cytopathology, and molecular diagnostics. Additionally, he underwent advanced training in molecular pathology at Tata Medical Centre, Kolkata, and Tata Memorial Centre, Parel, reinforcing his foundation in modern cancer diagnostics. His academic credentials are supported by multiple merit certificates from the Assam Higher Secondary Education Council, All Assam Students Union, and Assam Medical College, highlighting consistent academic distinction from secondary education through to his postgraduate years. This strong educational foundation has enabled Dr. Chowdhury to effectively lead both clinical and academic responsibilities in the field of oncopathology.

Professional Experience

Dr. Zachariah Chowdhury has accumulated rich and diverse professional experience across multiple prestigious institutions. He began his teaching career as a Senior Resident Doctor at the North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS), Shillong, where he served for three years post-MD, laying a strong foundation in clinical pathology and academic instruction. Currently, he serves as Professor and Officer-in-Charge of the Department of OncoPathology at MPMMCC & HBCH in Varanasi, both units under the Tata Memorial Centre. In this leadership role, he oversees academic training and diagnostic services in a high-volume cancer care setting. Dr. Chowdhury’s responsibilities include teaching DM (OncoPathology), MD (Pathology), MBBS, nursing, and laboratory science students in both theory and laboratory environments. His clinical expertise encompasses a wide spectrum, including histopathology, cytopathology, hematopathology, molecular diagnostics, clinical pathology, renal pathology, immunopathology, and blood banking. Additionally, he plays an active role in quality assurance programs within the diagnostic laboratory. Beyond his hospital commitments, he contributes to academia as a peer reviewer for multiple reputed medical journals and participates in national and international conferences as a speaker, panelist, and faculty. This blend of academic, clinical, and leadership experience underscores his stature as a seasoned medical professional.

Research Interest

Dr. Chowdhury’s research interests center around oncopathology with a multidisciplinary focus that integrates histopathology, molecular pathology, cytopathology, and hematopathology. His scholarly work investigates a wide range of oncological conditions, including breast cancer, thyroid lesions, ovarian tumors, pediatric malignancies, head and neck cancers, and hematolymphoid neoplasms. A key area of his research explores the diagnostic challenges and spectrum of rare tumors such as salivary gland neoplasms, solitary fibrous tumors, and angiosarcomas, with a special emphasis on cytohistological correlations and immunomorphological profiling. Additionally, he has contributed to understanding emerging themes like artificial intelligence in histopathology and the role of molecular diagnostics in rare malignancies. His recent studies include real-world clinical data on metastatic cancers and chemotherapy outcomes, bridging clinical practice with diagnostic research. Dr. Chowdhury’s commitment to evidence-based pathology is evident in his methodical approach to publishing both retrospective reviews and case-based literature, offering valuable insights to the global oncopathology community. His collaborations with multidisciplinary teams from oncology, radiology, and surgery reflect his integrative research philosophy. By focusing on both common diagnostic patterns and rare, underreported entities, his work not only advances academic pathology but also significantly contributes to clinical decision-making and patient outcomes.

Research Skills

Dr. Zachariah Chowdhury brings to the research landscape a comprehensive skill set encompassing classical and modern pathology techniques. He is proficient in histological examination, cytopathological evaluations (including FNAC and core biopsies), hematopathology analyses, and cutting-edge molecular diagnostics. His training at leading cancer centers like Tata Memorial Centre and Tata Medical Centre has equipped him with practical expertise in PCR, FISH, and immunohistochemistry techniques—essential tools in the molecular characterization of tumors. He also has expertise in immunomorphology and has applied these skills across a broad range of clinical cases, from pediatric cancers to high-grade lymphomas and soft tissue tumors. Dr. Chowdhury is also skilled in academic writing and statistical analysis, as evidenced by his extensive publication record across peer-reviewed indexed journals. His systematic approach to clinical audits, retrospective analyses, and diagnostic algorithm development further highlight his research rigor. Additionally, he has contributed to AI applications in cancer diagnosis, showcasing adaptability to new technologies. His experience in organizing research presentations and mentoring junior faculty and students also reflects strong leadership and team management skills within research settings. Altogether, his multidimensional research skills strongly align with the goals of translational oncology and precision medicine.

Awards and Honors

Dr. Chowdhury’s illustrious career has been recognized with numerous awards and honors, validating his significant impact in the field of pathology. Among the most notable are the Bharat Gaurav Puraskar (2023) and the Jewel of India Award (2024), both conferred by the KTK Outstanding Achievers and Education Foundation, New Delhi, for his exemplary contributions to pathology and medical education. During his academic years, he received multiple certificates of merit for academic excellence, including top ranks in both secondary and medical school examinations. His postgraduate performance earned him a Certificate of Merit from Assam Medical College. As a faculty member and researcher, he has consistently excelled in academic events, winning the first prize in Oral Paper Presentation at the 5th International Pediatric Pathology Conference (2022) and the Poster Presentation at NEIGRIHMS Annual Research Day (2018). His early career awards also include the North Eastern Council (NEC) Scholarship for MBBS, which supported his foundational medical education. Beyond these, his recognition extends to being a respected reviewer for multiple journals, and his frequent roles as invited speaker and panelist at various conferences. These accolades reflect both peer and institutional acknowledgment of his enduring impact on medical research and education.

Conclusion

Dr. Zachariah Chowdhury exemplifies the ideals of a clinician-scientist dedicated to excellence in oncopathology. With a firm grounding in both classical pathology and modern diagnostic innovations, he bridges the gap between histological diagnosis and translational cancer research. His career reflects a rare combination of clinical acumen, academic mentorship, research productivity, and institutional leadership. Through his prolific authorship of over 50 peer-reviewed publications, he contributes actively to the global understanding of complex and rare oncological entities. His commitment to education is evident in his multi-level teaching engagements and ongoing mentorship of pathology trainees. Dr. Chowdhury’s recognition through multiple national honors and academic awards further substantiates his role as a leading figure in cancer pathology in India. While already operating at a high level of academic and clinical distinction, future initiatives such as enhanced international collaborations, grant-funded research, and patent development would elevate his profile even further. Overall, Dr. Chowdhury represents a distinguished and highly qualified candidate for any recognition aimed at honoring pathologists and researchers who make substantial contributions to medical science, and particularly, to the evolving discipline of oncopathology.

Publications Top Notes

1. The many faces of ovarian sex cord stromal tumors: a clinicopathological analysis at a tertiary cancer center in North India

  • Year: 2025

  • Authors: Chowdhury Z, Agrawal S, Gupta S, Rai S, Jethani R, Saha S, Ranjan R, Pal A

  • Journal: Surgical and Experimental Pathology

2. The Myriad Spectrum of Salivary Gland Lesions: Cytohistological Correlation on Fine Needle Aspiration Cytology, Core Needle Biopsy, and Resections in a 5-Year Single Institutional Experience of North India

  • Year: 2025

  • Authors: Chowdhury Z, Majumdar P, Narain S, Lamba K

  • Journal: Diagnostic Cytopathology

3. ALK-positive large B-cell lymphoma: A study of six cases from an oncopathology center in North India

  • Year: 2025

  • Authors: Verma A, Chowdhury Z, Singh A, Kant A, Yadav A, Patne SCU

  • Journal: Indian Journal of Pathology and Microbiology

4. Cyto-Histomorphological Analysis of Thyroid Lesions and Risk Assessment of Malignancy/Neoplasia: Insights from a North Indian Tertiary Oncology Center

  • Year: 2025

  • Authors: Haiyat S, Chowdhury Z, Rudra Pal P, Patne S, Dhal I, Paul P

  • Journal: Cureus

5. An Analysis of Pediatric Round Cell Tumors Highlighting the Spectrum of Differential Diagnosis – A Single Center Experience and Systematic Review of Literature

  • Year: 2025

  • Authors: Dhal I, Lali BS, Rai H, Chowdhury Z, Patne S, Tripathi P, Saha S

  • Journal: International Journal of Scientific Studies

6. Real-world data on trastuzumab emtansine (TDM1) efficacy and safety: Results of a single-centre retrospective study of HER2-positive metastatic breast cancer patients

  • Year: 2025

  • Authors: Gupta A, Sansar B, Mishra BK, Khan A, Singh A, Upadhyay A, Chowdhury Z, Patne S, Tripathi M, et al.

  • Journal: Scientific Reports

7. Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study)

  • Year: 2025

  • Authors: Kapoor A, Gupta A, Sansar B, Mishra BK, Gupta P, Singh A, Upadhyay A, Kashyap L, Pal A, Kumar A, Nanda SS, Mukherji A, Kapoor AR, Pradhan S, Mishra A, Chowdhury Z, Patne S, Dhal I, Singh N, et al.

  • Journal: JCO Global Oncology

8. Exploring Solitary Fibrous Tumors at a Tertiary Cancer Center: Clinicopathological and Immunomorphologic Profile

  • Year: 2024

  • Authors: Chowdhury Z, Mishrikotkar S, Nehra P, Patne S, Tripathi M

  • Journal: Cureus

9. A Review of the Applications of Artificial Intelligence in Histopathology

  • Year: 2024

  • Authors: Kandarpa S, Chowdhury Z, Pal PR, Rajput K, Saraf SA

  • Journal: Journal of Cancer Research Reviews & Reports

10. Outcomes of De Novo Oligometastatic Breast Cancer Treated With Surgery of Primary and Metastasis Directed Radiotherapy

  • Year: 2024

  • Authors: Pujari L, Suresh A, Chowdhury Z, Pradhan S, Tripathi M, Gupta A, Singh P, Giridhar P, Kapoor AR, Shinghal A, Sansar B, Mv M

  • Journal: American Journal of Clinical Oncology

 

Guoguo Jin | Medicine and Dentistry | Best Researcher Award

Assoc. Prof. Dr. Guoguo Jin | Medicine and Dentistry | Best Researcher Award

Deputy Director from Key Laboratory of Chronic Disease Health Management of Henan Province, China

Dr. Guoguo Jin is an accomplished biomedical researcher specializing in the chemical prevention of tumors. With a strong foundation in pathology and bioengineering, she has steadily developed a research career that bridges cancer biology and cardiovascular complications arising from oncological treatments. Her work delves into the molecular mechanisms underlying tumorigenesis, cardiotoxicity from chemotherapeutic agents, and the identification of therapeutic targets for various cancers, particularly esophageal, gastric, and colon carcinomas. Dr. Jin currently serves as the Deputy Director of both the Key Laboratory of Chronic Disease Health Management and the Department of Scientific Research and Discipline Construction at Fuwai Central China Cardiovascular Hospital. She has led several national and provincial-level research projects and has published extensively in top-tier journals. Her research contributions are complemented by multiple patents aimed at mitigating drug-induced cardiotoxicity. Recognized for her leadership and scientific acumen, she has received accolades such as the Young and Middle-aged Academic Leader title from the Health Commission of Henan Province. Overall, Dr. Jin’s work represents a compelling blend of scientific rigor, clinical relevance, and translational potential. Her continued efforts are likely to yield significant advancements in cancer therapy and patient care.

Professional Profile

Education

Dr. Guoguo Jin began her academic journey in bioengineering, earning her Master’s degree from the School of Bioengineering at Zhengzhou University in July 2011. This foundational training equipped her with critical insights into biomedical sciences and experimental techniques. She then pursued her doctoral studies in pathology and pathophysiology at the Basic Medical College of Zhengzhou University, receiving her Ph.D. in July 2017. During her doctoral program, she was selected for an international joint training opportunity and spent two years (2015–2017) at the prestigious Hormel Institute, University of Minnesota. There, she conducted in-depth research into the signal transduction pathways related to tumorigenesis and its prevention. Her time abroad not only enriched her technical competencies but also exposed her to cutting-edge methodologies in cancer biology. This combination of local and international academic training has laid a solid foundation for her ongoing research into tumor mechanisms and therapeutic strategies. Dr. Jin’s educational background reflects a trajectory of consistent academic excellence and scientific curiosity, establishing her as a capable and knowledgeable researcher in the fields of oncology and pathology.

Professional Experience

Dr. Guoguo Jin currently holds dual leadership roles at Fuwai Central China Cardiovascular Hospital, where she serves as Deputy Director of both the Key Laboratory of Chronic Disease Health Management of Henan Province and the Department of Scientific Research and Discipline Construction. Her professional responsibilities primarily involve overseeing tumor-related research and institutional academic development. Earlier in her career, she gained international experience at the Hormel Institute, University of Minnesota, where she focused on cancer signal transduction pathways. This exposure to high-impact research environments significantly influenced her approach to scientific inquiry. Throughout her career, Dr. Jin has successfully led multiple research projects funded at both national and provincial levels. These projects explore the molecular mechanisms of drug-induced cardiotoxicity, tumor progression, and the discovery of small-molecule inhibitors. Her clinical and translational research activities are closely integrated with her hospital’s goals, enhancing the relevance and impact of her findings. With a strong blend of laboratory management, project leadership, and interdepartmental coordination, Dr. Jin’s professional journey reflects her growth from a bench scientist to an influential figure in medical research administration. Her dual roles in scientific research and academic governance enable her to contribute meaningfully to both science and institutional progress.

Research Interest

Dr. Guoguo Jin’s primary research interest lies in the chemical prevention of tumors, with a focus on uncovering the molecular mechanisms that drive carcinogenesis and treatment-related complications. She is particularly interested in the pathways that regulate tumor initiation and progression in gastrointestinal cancers such as esophageal, gastric, and colon cancer. A significant portion of her work also explores the cardiotoxic effects of chemotherapeutic agents like osimertinib and doxorubicin, aiming to develop strategies to mitigate these adverse outcomes. Her recent studies have investigated the roles of signaling molecules such as WNK1, hnRNPU, AHCY-LDHA, and ZIP8 in cancer development and progression. Dr. Jin is also deeply involved in the identification and evaluation of small-molecule inhibitors and natural compounds like α-mangostin and curcumin for their anti-tumor efficacy. Her research bridges basic science and clinical application, positioning her work at the forefront of translational oncology. Through the development of targeted therapies and predictive biomarkers, she aims to improve both treatment outcomes and quality of life for cancer patients. This integrated focus on cancer biology and cardiotoxicity underlines her commitment to advancing personalized medicine in oncology.

Research Skills

Dr. Guoguo Jin possesses a wide array of research skills, especially in molecular and cellular biology techniques relevant to oncology. She is proficient in signal transduction analysis, gene expression profiling, histone modification studies, and functional validation of oncogenes and tumor suppressors. Her expertise extends to the use of in vitro and in vivo cancer models to study the efficacy and mechanisms of chemopreventive agents. She has demonstrated a high level of competence in utilizing molecular techniques such as Western blotting, qRT-PCR, immunohistochemistry, and chromatin immunoprecipitation assays. Her postdoctoral training at the Hormel Institute allowed her to master advanced techniques for dissecting signaling pathways in cancer. In addition to experimental skills, Dr. Jin has a solid foundation in project design, grant writing, and data analysis. She is also skilled in translating laboratory findings into potential therapeutic applications, as demonstrated by her patents. Moreover, her ability to manage multidisciplinary teams and coordinate with clinical departments enhances the practical relevance of her research. These competencies enable her to effectively lead complex biomedical projects from conceptualization to execution and dissemination.

Awards and Honors

Dr. Guoguo Jin has received multiple awards and honors that underscore her impact and promise in the field of medical research. In February 2024, she was selected as a Young and Middle-aged Academic Leader in Health and Wellness by the Health Commission of Henan Province, a recognition of her leadership in translational cancer research. Later that year, she was awarded a position in the National-Level Talent Cultivation Project for First-Class Discipline in Clinical Medicine at Zhengzhou University. Dr. Jin has also secured several competitive research grants, including the National Natural Science Foundation Youth Project, the Science and Technology Tackling Project by the Department of Science and Technology of Henan Province, and the Outstanding Young Talent Training Program for Health and Technology Innovation. Her innovative research on cancer prevention and cardiotoxicity has led to two patents, further highlighting her commitment to developing clinically relevant solutions. These accolades reflect not only her scientific excellence but also her dedication to advancing health outcomes through rigorous and applied research. The consistent support from national and provincial agencies illustrates her status as a leading figure in her domain.

Conclusion

Dr. Guoguo Jin exemplifies the qualities of a leading researcher with her focused expertise in chemical tumor prevention and translational oncology. Her well-rounded background—from robust academic training to leadership in high-impact research—positions her as a valuable contributor to both the scientific community and clinical practice. Her studies on molecular mechanisms of cancer progression and cardiotoxicity have not only expanded academic understanding but have also offered practical pathways for improving patient outcomes. Through national and provincial grants, influential publications, and patented innovations, she continues to push the boundaries of cancer therapy and prevention. While her research is already making a meaningful impact, future expansion into international collaborations and clinical trials could further elevate her contributions. Overall, Dr. Jin’s career is marked by scientific rigor, visionary leadership, and a commitment to translating research into real-world solutions. She is a highly deserving candidate for recognition through honors such as the Best Researcher Award and is likely to make even greater strides in cancer research in the years to come.

Publications Top Notes

  1. Title: STIP1 drives metabolic reprogramming in esophageal squamous cell carcinoma via AHCY-LDHA axis
    Authors: Jin G, Song Y, Yan M, Fang S, Shao Y, Zhao K, Liu M, Guo Q, Jia X, Zhang C, Wang Z, Liu K, Li X, Zhao S, Guo Z, Dong Z
    Year: 2025

  2. Title: hnRNPU-mediated pathogenic alternative splicing drives gastric cancer progression
    Authors: Jin G, Song Y, Fang S, Yan M, Yang Z, Shao Y, Zhao K, Liu M, Wang Z, Guo Z, Dong Z
    Year: 2025

  3. Title: ZIP8 modulates ferroptosis to drive esophageal carcinoma progression
    Authors: Yang Z, Zhao K, Li X, Yanzhang R, Zhang H, Yu Y, Yan M, Fang S, Li T, Li H, Chu X, Han S, Zhang Z, Teng J, Jin G, Guo Z
    Year: 2025

  4. Title: Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer
    Authors: Jin G, Yan M, Liu K, Yao K, Chen H, Zhang C, Yi Y, Reddy K, Gorja DR, Laster KV, Guo Z, Dong Z
    Year: 2020

  5. Title: Ginger extract inhibits c-MET activation and suppresses osteosarcoma in vitro and in vivo
    Authors: Yanzhang R, Yan M, Yang Z, Zhang H, Yu Y, Li X, Shen R, Chu X, Han S, Zhang Z, Teng J, Li H, Li T, Jin G, Guo Z
    Year: 2025

  6. Title: PDK1-mediated phosphorylation of USP5 modulates NF-κB signalling to enhance osteosarcoma growth
    Authors: Yang Z, Yu Z, Teng J, Yanzhang R, Yu Y, Zhang H, Jin G, Wang F
    Year: 2025

  7. Title: Precision therapy for cancer prevention by targeting carcinogenesis
    Authors: Jin G, Liu K, Guo Z, Dong Z*
    Year: 2024

  8. Title: Decrypting the Molecular Mechanistic Pathways Delineating the Chemotherapeutic Potential of Ruthenium-Phloretin Complex in Colon Carcinoma Correlated with the Oxidative Status and Increased Apoptotic Events
    Authors: Jin G, Zhao Z, Chakraborty T, et al.
    Year: 2020

  9. Title: Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma
    Authors: Zhao Z, Jin G, Yao K, Liu K, Liu F, Chen H, Wang K, Gorja DR, Reddy K, Bode A.M., Guo Z, Dong Z
    Year: 2019

  10. Title: Resveratrol suppresses colon cancer growth by targeting the AKT/STAT3 signaling pathway
    Authors: Li D, Wang G, Jin G, Yao K, Zhao Z, Bie L, Guo Y, Li N, Deng W, Chen X, Chen B, Liu Y, Luo S, Guo Z
    Year: 2019

Kumiko Tajima | Medicine and Dentistry | Women Researcher Award

Dr. Kumiko Tajima | Medicine and Dentistry | Women Researcher Award

Manager from Gunma Central Hospital, Japan

Kumiko Tajima is a highly qualified medical professional with extensive experience in internal medicine and diabetes care. She graduated from Gunma University School of Medicine in 1992 and completed graduate studies at Gunma University Graduate School in 1999. With over two decades of clinical practice, she has served at several prominent medical institutions in Japan, including Gunma University School of Medicine, National Takasaki Hospital, and Gunma Prefectural Cardiovascular Center. Since 2014, she has been practicing at Gunma Central Hospital. Kumiko is recognized as a certified physician by the Japanese Society of Internal Medicine and specializes in general internal medicine and diabetes management. Her career is marked by a strong commitment to patient care, education, and specialized training, including roles as an instructor for medical training programs. She also serves vulnerable populations as a designated physician for disabilities and intractable diseases. While her clinical expertise is well documented, her research involvement is not explicitly detailed in the information available, suggesting a potential focus on clinical practice and medical education over research output. Nevertheless, her professional credentials and dedication to healthcare highlight her as a respected figure in the medical community.

Professional Profile

Education

Kumiko Tajima completed her formal education at Gunma University, one of Japan’s reputable institutions. She graduated from the Gunma University School of Medicine in 1992, where she acquired the foundational knowledge and clinical skills required to pursue a medical career. Following her medical degree, she advanced her expertise by completing graduate studies at Gunma University Graduate School in 1999. This postgraduate education likely included clinical research or advanced medical training, equipping her with enhanced knowledge in medical sciences. Her educational background provided a strong base for her subsequent clinical work and certifications in various medical specialties. Being an alumna of the same university for both undergraduate and graduate studies suggests continuity and depth in her academic preparation. Her education set the stage for her later roles in internal medicine, diabetes specialization, and her involvement in training programs. The rigorous training at Gunma University, known for its emphasis on both research and clinical practice, has likely influenced her professional trajectory, balancing patient care with medical education.

Professional Experience

Kumiko Tajima has accumulated significant clinical experience working in multiple prestigious medical institutions across Japan. Early in her career, she worked at Gunma University School of Medicine, which provided her with exposure to academic medicine and clinical research environments. She also served at National Takasaki Hospital, Tatebayashi Kosei Hospital, and Gunma Prefectural Cardiovascular Center, gaining diverse experience in patient care across various specialties and healthcare settings. Since 2014, she has been a key medical professional at Gunma Central Hospital, where she continues to provide specialized care in internal medicine and diabetes management. Throughout her career, she has been recognized for her expertise by multiple Japanese medical societies, reflected in her qualifications as a certified physician and specialist. She holds important roles such as a training instructor for diabetes care and general medical training, indicating her leadership in mentoring younger physicians. Additionally, her designation as a physician under the Welfare Act for the Physically Disabled and for intractable diseases highlights her involvement in public health and complex patient populations. Her extensive clinical roles demonstrate a strong foundation in both patient care and medical education.

Research Interests

While explicit details about Kumiko Tajima’s research interests are not provided in the information available, it is reasonable to infer that her research focus aligns closely with her clinical specialties—internal medicine and diabetes. Given her certifications and instructor roles within the Japan Diabetes Society, she likely engages with research related to diabetes management, treatment outcomes, and possibly public health aspects of chronic diseases. Her designation as a physician responsible for intractable diseases suggests potential interest in complex, difficult-to-treat conditions that may require innovative clinical approaches or translational research. Moreover, her role in general medical training indicates a probable interest in medical education research or clinical practice improvement. Without specific publications or ongoing research projects mentioned, her primary contributions may be in applying clinical knowledge to patient care and educating the next generation of physicians. If involved in research, it may focus on improving clinical protocols, diabetes education, or interdisciplinary care for chronic disease patients. Confirmation of such interests would strengthen her profile as a clinician-researcher.

Research Skills

Kumiko Tajima’s documented expertise suggests strong clinical skills particularly in internal medicine, diabetes care, and training future medical professionals. As a certified specialist and instructor in diabetes, she likely possesses advanced skills in managing complex cases, interpreting clinical data, and applying evidence-based medicine. Her role as an industrial physician and designated physician for the disabled reflects proficiency in occupational health and specialized patient management. Although there is no explicit mention of laboratory or bench research skills, her graduate education and clinical roles imply familiarity with clinical research methodologies, patient data analysis, and possibly clinical trial participation. Her instructional roles also suggest capabilities in curriculum development, clinical supervision, and medical education, which are important research-adjacent skills. If involved in research activities, these skills would be foundational for clinical studies, epidemiological research, or healthcare quality improvement projects. To enhance her research profile, further skills in scientific writing, grant applications, and collaboration in research networks would be beneficial.

Awards and Honors

The provided information does not list any specific awards or honors received by Kumiko Tajima. However, her qualifications as a certified physician by reputable Japanese medical societies, and her appointment as a specially appointed instructor for general medical training, indicate professional recognition within the medical community. These certifications and instructor roles can be seen as professional honors reflecting her expertise and dedication to clinical excellence and education. Additionally, her designation as a physician for intractable diseases and disabilities suggests recognition of her specialized skills and trust placed in her by public health authorities. While no formal awards are cited, her career achievements and appointments demonstrate a high level of respect and acknowledgment from her peers and regulatory bodies. Should she have received awards related to clinical innovation, research contributions, or teaching excellence, including these would enhance her profile for awards specifically focused on research.

Conclusion

Kumiko Tajima is an experienced and highly qualified medical professional with strong credentials in internal medicine and diabetes care. Her clinical expertise, long-standing service in multiple hospitals, and roles in medical training and specialized care demonstrate her dedication to both patient health and medical education. While she holds numerous certifications and leadership roles within professional medical societies, her profile lacks explicit information on research outputs, publications, or scientific contributions. For a Women Researcher Award focused on research excellence, evidence of active research involvement or scholarly achievements would be necessary to strengthen her candidacy. Nevertheless, her commitment to specialized clinical care, training, and vulnerable patient populations underscores her valuable role in the healthcare system. If supplemented by further details on her research activities, Kumiko Tajima could be a strong candidate. Currently, her profile is more aligned with clinical leadership and education, rather than research-centric recognition.

Publications Top Notes

  1. A case of SHORT syndrome with a novel genetic mutation diagnosed 19 years after the onset of diabetes

    • Authors: Kumiko Tajima, Yushi Hirota, Tomofumi Takayoshi, Wataru Ogawa

    • Year: 2025

  2. Medical Mystery: Abnormal Abdominal Radiograph — The Answer

    • Authors: Masahiko Kurabayashi, Kumiko Tajima

    • Year: 2007

  3. Medical Mystery — Abnormal Abdominal Radiograph

    • Authors: Kumiko Tajima, Masahiko Kurabayashi

    • Year: 2006